Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Beginning Cash Balance: 2010-2021

Historic Beginning Cash Balance for Neurocrine Biosciences (NBIX) over the last 12 years, with Dec 2021 value amounting to -$29.7 million.

  • Neurocrine Biosciences' Beginning Cash Balance fell 106.93% to -$29.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$153.7 million, marking a year-over-year decrease of 233.07%. This contributed to the annual value of $18.1 million for FY2024, which is 56.03% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Beginning Cash Balance stood at -$29.7 million for Q4 2021, which was down 108.07% from $368.0 million recorded in Q3 2021.
  • Over the past 5 years, Neurocrine Biosciences' Beginning Cash Balance peaked at $428.5 million during Q4 2020, and registered a low of -$29.7 million during Q4 2021.
  • In the last 3 years, Neurocrine Biosciences' Beginning Cash Balance had a median value of $177.8 million in 2019 and averaged $212.1 million.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first spiked by 258.85% in 2017, then slumped by 106.93% in 2021.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Beginning Cash Balance stood at $267.9 million in 2017, then fell by 26.95% to $195.7 million in 2018, then decreased by 13.85% to $168.6 million in 2019, then soared by 154.15% to $428.5 million in 2020, then slumped by 106.93% to -$29.7 million in 2021.
  • Its last three reported values are -$29.7 million in Q4 2021, $368.0 million for Q3 2021, and $352.6 million during Q2 2021.